Isis upbeat on prospects for US Kynamro approval and promising pipeline
This article was originally published in Scrip
Following an upbeat second quarter earnings report on 6 August and guidance for the rest of the year, antisense drug developer Isis Pharmaceuticals announced an offering of $175 million of convertible senior notes to repurchase debt previously issued by the company, to repurchase or redeem existing convertible notes and for general expenses.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.